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What’s new? 
• A microsimulation model of the diabetic retinopathy screening and treatment 
pathways in Scotland was developed; incorporating risks of progression estimated 
from contemporary, longitudinal, population-based screening outcome data. 
• The adoption of biennial screening intervals for those with diabetes and no diabetic 
retinopathy is likely to be cost-effective. 
• There is greater uncertainty surrounding the long-term cost-effectiveness of biennial 
screening in younger people with Type 1 diabetes and no retinopathy, due to the 
higher long-term cumulative risk of developing interval referable disease, and a lower 
competing risk of death from all causes. 
 
Abstract 
Aims  To assess the cost-effectiveness of adopting risk-stratified approaches to extended 
screening intervals in the national diabetic retinopathy screening programme in Scotland. 
Methods  A continuous-time hidden Markov model was fitted to national longitudinal 
screening data to derive transition probabilities between observed non-referable and referable 
retinopathy states. These were incorporated in a decision model simulating progression, costs 
and visual acuity outcomes for a synthetic cohort with a covariate distribution matching that 
of the Scottish diabetic screening population. The cost-effectiveness of adopting extended 
(2-year) screening for groups identified as low risk was then assessed over a 30-year time 
horizon. 
Results  Individuals with a current grade of no retinopathy on two consecutive screening 
episodes face the lowest risk of progressing to referable disease. For the cohort as a whole, 
the incremental cost per quality-adjusted life year gained for annual vs. biennial screening 
ranged from  approximately £74 000 (for those with no retinopathy and a prior observed 
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grade of mild or observable background retinopathy) to approximately £232 000 per quality-
adjusted life year gained (for those with no retinopathy on two consecutive screening 
episodes). The corresponding incremental cost-effectiveness ratios in the subgroup with 
Type 1 diabetes were substantially lower; approximately £22 000 to £85 000 per quality-
adjusted life year gained, respectively. 
Conclusions  Biennial screening for individuals with diabetes who have no retinopathy is 
likely to deliver significant savings for a very small increase in the risk of adverse visual 
acuity and quality of life outcomes. There is greater uncertainty regarding the long-term cost-
effectiveness of adopting biennial screening in younger people with Type 1 diabetes. 
 
Introduction 
The Scottish diabetic retinopathy screening programme was established in late 2005, based 
on a system of annual screening of all those with diabetes (aged ≥ 12 years) using digital 
retinal photography. The programme screened 199 268 (80.7%) eligible people in 2013/2014 
[1]. With the prevalence of diabetes increasing by 4% annually in Scotland [2], costs of 
screening are set to rise unless efficiency gains can be realized. 
Although the early identification and treatment of people at risk of sight loss from 
proliferative diabetic retinopathy is clearly beneficial, many people currently screened 
annually have no visible signs of retinopathy (or evidence of only mild disease). A number of 
cohort studies have demonstrated that such people face a low risk of developing referable 
disease within 1 year [3,4], suggesting efficiency gains could be achieved with the selective 
application of extended screening intervals. Consequently, the National Health Service 
(NHS) National Screening Committee has recently recommended that screening intervals 
might be extended to 2-yearly in those at low risk based on the results of two screening 
episodes [5,6]. 
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Several modelling studies have assessed the cost-effectiveness of adopting extended intervals 
for individuals at low risk of progression to referable disease, but these have produced mixed 
findings, due in part to differences in the estimated underlying risks of progression [7]. The 
aim of this study was to assess the cost-effectiveness of adopting a risk-stratified approach to 
extended screening intervals using contemporary data from the national screening programme 
in Scotland. 
 
Patients and methods 
 
Screening and grading protocol 
People eligible for screening in Scotland are identified via the National Diabetes Registry—
the Scottish Care Information-Diabetes Collaboration (SCI-DC) database—which 
automatically captures data on people with a diagnosis code for diabetes. It has an estimated 
coverage of > 99% of the diagnosed population. The screening examination involves single 
central 45° field digital photographs with mydriasis if required, which are graded centrally 
using a quality-assured grading system [8]. 
The grading system provides a retinopathy (R) grade and a maculopathy (M) grade [9]. 
Action is determined by the most severe finding in the worst eye with grades of R3 (referable 
background retinopathy), R4 (proliferative retinopathy) and M2 (referable maculopathy) 
triggering referral to a specialist eye clinic. Individuals with no (R0) or mild (R1) background 
retinopathy are currently recalled to screening at 1 year, whereas those with observable 
disease (R2 and/or M1) are recalled at 6 months. 
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Overview of the modelling approach 
In this study, we used observed data on screening outcomes to derive transition probabilities 
between non-referable and referable retinopathy states. A decision analytic model was then 
used to simulate the progression of a synthetic cohort with a covariate distribution matching 
that of the Scottish diabetic screening population. Downstream risks of visual loss associated 
with referable disease, health and social care costs, and health state utility data were 
incorporated in the model based on the existing literature. The cost-effectiveness of adopting 
alternative risk-stratified approaches to extended screening intervals was then assessed. 
 
Derivation of transition probabilities 
The methods for deriving transition probabilities from the longitudinal screening data are 
described in detail elsewhere [4]. The dataset held by SCI-DC provided outcome data from 
sequential screening visits for 255 712 individuals who had at least one screening exam 
between October 2005 and November 2011. The median [interquartile range (IQR)] number 
of screening visits was 4 (2–5) and the median (IQR) interval between visits was 54 (51–
59) weeks. In total, 11 201 cases of referable background (R3) or proliferative retinopathy 
(R4), and 25 333 cases of referable maculopathy (M2) were observed over follow-up. As well 
as information on screening outcomes, the dataset contains clinical and demographic 
variables, including type of diabetes, diagnosis date, sex and age. 
To allow for misclassification, a continuous-time hidden Markov model was fitted to the 
screening data using the MSM package for R [10], and then used to examine the effect of 
individual level covariates on the transitions between four discrete observed states: (1) no 
visible retinopathy (R0); (2) mild background retinopathy (R1); (3) observable background 
retinopathy or maculopathy (R2/M1); and (4) referable retinopathy or maculopathy (R3, R4, 
M2). The model specified four hidden states corresponding to these four observed states, 
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each with a vector of emission probabilities. The Q matrix of transition rates was constrained 
to allow transitions only between adjacent hidden states, and the emission probabilities were 
constrained to allow misclassification only to observed states adjacent to the hidden state. 
State 4 was modelled as an absorbing state—no transition to a less severe state can occur. 
Two covariates—sex and duration of diabetes—were included in the model as effects on the 
transition rates between hidden states. Using this approach, the model-based probabilities of 
observing a transition to referable disease (R3, R4 or M2) over ensuing time intervals (up to 
3 years) were calculated by type of diabetes, sex, diabetes duration and current/prior observed 
retinal photographic screening grade. 
 
Economic modelling 
The characteristics of the simulated cohort were based on a random sample (n = 7349) of the 
Scottish screening cohort (Table 1). The decision model (Fig. 1) was used to simulate 
progression on a 3-monthly cycle for those with non-referable disease (state 1, 2 or 3), no 
history of referable disease and complete descriptive data (n = 6348; 86.4%). Details of the 
model and the input parameter values are provided in Appendix S1 (Tables S1–S3). An 
overview is provided below. 
The transition probabilities between observed retinopathy states were incorporated and 
referenced by the characteristics of simulated individuals in the economic model. Because 
there are currently insufficient rounds of screening to assess observed transitions in the longer 
term, duration of diabetes and the expected current and prior screening grades of simulated 
individuals were updated every 12 months, and the onward 1- and 2-year probabilities of 
progression to referable disease were reset every 24 months based on these updated 
characteristics. Probabilities of developing referable disease were expressed as 3-monthly 
probabilities, in keeping with model cycle length. 
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Incident referable disease was disaggregated to M2, R3 and R4 based on observed screening 
data. 
For referable maculopathy (M2) with diabetic macular oedema (DMO) left untreated [11], a 
30% risk of moderate visual loss [≥ 15 Early Treatment of Diabetic Retinopathy Study 
(ETDRS) letters] was modelled over 3 years [12]. Focal laser treatment was assumed for 
identified asymptomatic DMO not involving the centre of the macula, reducing the risk of 
vision loss by 50% [12,13]. Intravitreal ranibizumab injections [14] were modelled for 
symptomatic DMO (visual acuity ≤ 75 ETDRS letter), with visual acuity outcomes matching 
those observed at 2 years in the Diabetic Retinopathy Clinical Research Network Protocol I 
trial [15]. Following this, a simple natural history model was applied reflecting the tendency 
for vision to decline slowly over time [16,17]. 
The untreated risks of progression from R3 to R4 (11.5% per year) and from R4 to severe 
visual loss (8.8% per year) were identified from the published literature [18–20]. Treatment 
with pan-retinal photocoagulation was modelled to confer an 80% relative risk reduction for 
severe visual loss [19,21]. Individuals suffering severe visual loss (visual acuity ≤ 25 ETDRS 
letters) were modelled to undergo early vitrectomy, with 66% achieving visual acuity > 35 
(mean 50) ETDRS letters [22]. For those with binocular sight-threatening disease, the risk of 
visual loss in each eye was modelled independently. Mortality was modelled based on 
age/sex-specific UK life tables combined with standardized mortality ratios reflecting the 
increased risk of death associated with Type 1 and Type 2 diabetes [23,24]. 
 
Costs 
Costs associated with photographic screening (£35.98 per visit), optical coherence 
tomography monitoring (£33.14 per visit) [11], referral and treatment [25–27], and long-term 
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health and social care [22,28] were incorporated in the model (Table S1). All costs were 
expressed in 2012–2013 pounds sterling [26]. 
 
Quality-adjusted life years 
The survival time of simulated individuals was quality adjusted using health state utility 
weights reflecting the desirability of their modelled visual acuity status. This approach 
allowed quality-adjusted life years (QALYs) to be estimated. Uncertainty exists as to how 
vision loss in one or both eye(s) affects health-related quality of life. A conservative approach 
was adopted, whereby health state utilities associated with visual acuity in the worse-seeing 
eye [16] were referenced for those with two good eyes (visual acuity> 35 ETDRS letters) at 
baseline, with best-seeing eye utility values [29] applied if vision dropped to ≤ 35 letters in 
both eyes. Utility values associated with visual acuity in the best-seeing eye [29] were 
referenced for simulated individuals with only one good eye at baseline. We also report 
expected differences in the incidence of moderate visual loss and severe visual loss or 
vitrectomy. These estimates do not account for the fact that visual impairment is at least 
partly reversible in a significant proportion of cases. 
 
Screening strategies 
The analysis focused on the impact of adopting 2-year screening intervals in subgroups of 
individuals with no retinopathy and duration of diabetes ≤ 25 years. Screening programme 
sensitivity was estimated to be 0.857 based on the reported sensitivities of graders operating 
at different levels within the grading system in Scotland [8,30,31]. Screening uptake was set 
at 80% [1] and it was conservatively assumed that individuals do not present to 
ophthalmology services unless identified through the screening programme. The following 
strategies were compared: 
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1. Current practice—annual screening for those with no or mild retinopathy, 6-monthly 
screening for observable retinopathy/maculopathy; 
2. Two-year intervals for those with no retinopathy; 
3. Two-year intervals for those with no retinopathy at first screen or no retinopathy 
observed at two consecutive screening episodes; and 
4. Two-year interval for those observed with no retinopathy at two consecutive 
screening episodes. 
Individuals developing any retinopathy were returned to current practice once identified. It 
was also conservatively assumed that individuals missing an appointment would remain on 
their assigned interval until their next screen. Secondary analyses considered separately the 
subgroup with Type 1 diabetes. 
 
Analysis 
Monte Carlo simulation was used to propagate the passage of individuals through the model 
one at a time. Modelled costs and QALYs were discounted at a rate of 3.5% per annum [32]. 
Incremental cost-effectiveness ratios (ICERs), reflecting the difference in mean costs over the 
difference in mean QALYs between two strategies, were calculated for more effective 
strategies vs. the next less effective option. To help interpret the ICERs, a threshold 
willingness-to-pay ratio of £30 000 per QALY was applied [32]. Probabilistic sensitivity 
analysis was carried out by assigning a probability distribution (Table S1) to each model 
input parameter and analysing the model 1000 times, each time using a randomly selected 
value for each input parameter from its assigned distribution [33]. Deterministic sensitivity 
analysis assessed the impact of varying parameter values and structural assumptions 
individually and in combination. A further exploratory analysis assessed the 1-year 
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progression risk above which annual screening may become cost-effective compared with 
biennial screening. 
 
Results 
 
Model-based transition probabilities 
The estimated risks of progression derived from the analysis of the national longitudinal 
screening data are tabulated in Tables S2 and S3. 
Individuals with a current grade of no retinopathy and a prior grade of no retinopathy (or no 
prior screen) face the lowest risk of progressing to referable disease. As reported previously 
[4], prior screening grades improve the prediction of subsequent transition beyond the current 
state; for example, those with no retinopathy and a prior grade of observable or mild 
retinopathy face a higher risk of progression than those with no retinopathy previously 
observed. 
 
Economic analysis 
Table 2 summarizes the projected mean costs and outcomes at 3 years for the alternative 
screening strategies. The 2-year interval strategies result in health service cost savings for 
very small increases in the incidence of visual loss. For example, strategy 3 results in an 
expected saving of approximately £19 per patient, for an increase in the incidence of 
moderate and severe visual loss/vitrectomy of 1–2 per 100 000 screened. Economic cost 
savings at the population level would equate to approximately £3.3 million 
(£19  200 000  0.864) over 3 years. 
Tables 3 and 4 present the results of applying the alternative interval strategies iteratively 
over 30 years. Over time the cumulative differences in costs and outcomes between the 
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strategies increase, with the biennial strategies leading to an increase in the cumulative 
incidence of moderate visual loss of 36–54 per 100 000, or severe visual loss/vitrectomy (in 
any eye) of 31–46 per 100 000. However, the ICERs for the more effective strategies remain 
very high. For example, current practice is estimated to cost an extra £232 290 per QALY 
gained compared with the strategy involving the targeted use of biennial screening for those 
with no retinopathy on two consecutive screening episodes. 
Table S4 (Appendix S2) replicates the above analysis for those with Type 1 diabetes. In this 
subgroup, the ICER is £21 740 per QALY gained for annual vs. biennial screening for those 
with a current grade of no retinopathy and a prior grade of mild/observable retinopathy. The 
ICER for current practice is estimated to be £85 399 per QALY gained compared with the 
selective use of biennial intervals for those with no retinopathy on two consecutive screening 
episodes. The increases in cumulative incidence of moderate visual loss and severe visual 
loss/vitrectomy range from 24 to 36 per 100 000 and from 32 to 50 per 100 000, 
respectively—with the smaller increases being associated with the selective use of biennial 
intervals in those with no retinopathy on two consecutive screening episodes (Table S5). 
 
Deterministic sensitivity analysis 
Table S6 (Appendix S2) presents the results of deterministic sensitivity analyses. For the 
cohort as whole, the findings are generally robust to changes in key input parameters. If 
individuals on a biennial interval who miss a screening visit are recalled to annual screening, 
this greatly reduces the increased incidence of moderate visual loss and severe visual 
loss/vitrectomy associated with the biennial screening (by approximately 80–85%), and 
greatly increases the ICERs for annual screening. The ICERs for current practice were also 
found to be similarly high when applying the biennial interval strategies irrespective of 
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diabetes duration; £209 014 and £94 693 per QALY gained for the cohort as a whole and the 
Type 1 cohort, respectively (Table S6, scenarios 18 and 19). 
 
Risk threshold analysis 
Applying conservative assumptions, the risk threshold analysis suggests that the ICER for 
annual vs. biennial screening may fall below £30 000 when the 1-year risk of progression 
rises above ~ 4.3% for those with Type 2 diabetes, or above ~ 1.4% for those with Type 1 
diabetes. When the risk of progression is below ~ 0.5% in those with Type 2 diabetes, the 
additional cost per QALY gained for annual vs. biennial screening rises above £100 000. 
However, for Type 1 diabetes, the ICER for annual screening only rises above £100 000 
when the 1-year risk of progression drops below ~ 0.2%. 
 
Probabilistic sensitivity analysis 
The results of the probabilistic sensitivity analysis comparing the 2-year interval strategies 
are summarized in Fig. 2. These indicate that strategy 2 (2-year intervals for all those with no 
diabetic retinopathy) has the highest probability of being cost-effective at willingness to pay 
of £30 000 per QALY gained. Figure S1 presents the probabilistic results for those with 
Type 1 diabetes. 
 
Discussion 
This study suggests that the magnitude of any increase in the incidence of visual loss, with 
the adoption of biennial screening for those with no diabetic retinopathy, is likely to be very 
small. Biennial screening for those with no retinopathy on two consecutive screening 
episodes generated ~ 36 additional cases of moderate or severe visual loss per 100 000 over 
30 years. However, a good proportion of these cases would be expected to improve following 
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appropriate treatment [22,34]. In addition, conservative assumptions were applied in the 
model to guard against underestimating the risk of interval referable disease progressing to 
proliferative retinopathy. It may, therefore, overestimate the long-term risks of visual loss and 
modelled cumulative differences between the strategies on this outcome. Furthermore, most 
of the additional cases of visual loss (80–85%) occurred in the second year following a 
missed screening episode, in individuals on a biennial interval who were modelled to go a 
further 2 years before being recalled. In reality, such individuals could be recalled earlier to 
annual screening, greatly reducing any increase in the risk of visual loss. Conversely, the 
corresponding cost savings with biennial screening are relatively large, equating to 
approximately £8.1 million (net present value) per 100 000 for the most conservative biennial 
screening strategy. 
For the cohort as a whole, the base case ICERs for annual vs. biennial screening ranged from 
approximately £74 000 (for those with no retinopathy and a prior observed grade of mild or 
observable retinopathy) to approximately £232 000 per QALY gained (for those with no 
retinopathy on two consecutive screening episodes). The ICERs for annual screening in those 
with Type 1 diabetes were lower due to a lower competing risk of death and a slightly higher 
proportion of incident referable disease being R3/R4. However, the ICER for annual 
screening in those with no retinopathy on two consecutive screens remained well above 
£30 000 per QALY [32]. The model findings were generally found to be robust to changes in 
key parameters and assumptions, with the ICER for current practice remaining above £30 000 
per QALY. The findings in the Type 1 subgroup were somewhat more sensitive. However, if 
individuals on a biennial interval who miss a screening visit are recalled to annual screening, 
this greatly increases the ICERs for annual vs. biennial screening in all cohorts. 
Applying conservative modelling assumptions, the ICER for annual vs. biennial screening, in 
those with Type 2 diabetes, was found to fall below £30 000 when the 1-year risk of 
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progression was above ~ 4.3%. In those with Type 1, diabetes the corresponding risk 
threshold was ~ 1.4%. These thresholds may, in reality, be higher. For comparison, the 
observed one-year probabilities of progression among individuals with no diabetes on two 
consecutive screening episodes were recently reported to vary between 0.1% and 0.6% across 
seven UK based screening programmes [35]. 
 
Strengths and limitations 
The risks of progression to referable disease, in the short term, were derived from 
longitudinal Scottish population-based screening data. In addition, care was taken to ensure 
the modelled screening and downstream monitoring/treatment pathways were consistent with 
current clinical practice. By using a microsimulation approach, we were also able incorporate 
heterogeneity in the simulated cohort and dynamically adjust intervals to the modelled 
screening history of simulated individuals. 
The long-term analysis assumes that the estimated short-term transition probabilities between 
observed retinopathy states—referenced by sex, current/prior grade and type/duration of 
diabetes—are valid for predicting future progression based on modelled updating of the time-
varying characteristics of the simulated cohort. Given that the longitudinal screening data 
cover a median of four screening visits, this is an uncertain assumption. Any decision to 
adopt wider intervals iteratively over time (based on these criteria) should be carefully 
monitored and reviewed. As more data become available on the ongoing risk of progression, 
more sophisticated ways of identifying those at low risk of progression may be identified. A 
further caveat of the analysis is that the progression risks were derived from screening data 
collected primarily before the introduction of automated grading in Scotland. However, 
because automated grading was found to have similar sensitivity to manual disease/no disease 
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grading (i.e. the task it replaces in the Scottish grading system) [30,31], we do not expect this 
to have a material impact on our findings. 
Owing to a lack of contemporary data on the progression of untreated referable retinopathy in 
the Scottish context, the economic modelling relied on assumptions and older natural history 
data to inform this. Therefore, estimated visual loss and QALY losses associated with 
biennial screening may be overestimated if the contemporary post-referral disease 
progression rates are lower than in the 1970s/1980s due to changes in the management of risk 
factors. This seems plausible because glycaemic and blood pressure management is much 
more aggressive now compared with the 1970/1980s [36–38]. It would be beneficial to 
conduct further observational studies to better inform this area of uncertainty. 
The model adopted a health and social care perspective in line with NICE guidelines for 
evaluating health technologies in the UK NHS [32]. However, it is acknowledged that visual 
impairment has a broader impact on costs to individuals and society as a whole, which have 
not been captured here. Furthermore, there is a paucity of data on the health and social care 
costs associated with legal blindness in the UK, and those included in the model were 
estimated for older people with age related macular degeneration [28]. Therefore, the model 
based results are likely more robust for older groups with Type 2 diabetes. 
 
Comparison with other similar studies 
The majority of cost-effectiveness studies that have assessed the use of extended screening 
intervals have concluded that similar clinical outcomes can be achieved at lower cost in those 
with no or mild retinopathy [7]. Although three prior modelling studies concluded that annual 
screening is more cost-effective [39–41], these studies applied higher aggregate risks of 
progression than those estimated for individuals with no retinopathy in the contemporary 
Scottish cohort. 
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Scanlon et al. recently conducted a comprehensive modelling study assessing the impact of 
adopting risk-stratified screening intervals in the national screening programme in England 
[42]. They similarly informed progression risks using multistate modelling of longitudinal 
screening data, and embedded these in a Markov decision model. For those with no 
retinopathy on two consecutive screening episodes, they estimated that the adoption of 2-year 
screening intervals would save on average £225 000 per QALY lost compared with annual 
screening. Our comparable estimate is £232 290 per QALY lost for a similar policy. Scanlon 
et al. also estimated a saving of £113 823 per QALY lost for 3-year vs. 2-year intervals in 
this low-risk group. Given the many uncertainties regarding the impact and risk of visual loss 
following the development of referable disease in the Scottish context, we focused on 
assessing the robustness of the cost-effectiveness findings for biennial intervals. However, it 
is entirely plausible that even wider intervals may be cost-effective against standard 
thresholds in low-risk groups. 
 
Implications for policy 
This study generally supports the adoption of extended 2-year screening intervals for 
individuals with diabetes who have no retinopathy. The adoption of explicit criteria for 
extended screening intervals would free up resources for reinvestment, allowing screening 
programmes to meet increasing demand within budget constraints, whilst guarding against 
the passive slippage of screening intervals due to capacity constraints. Furthermore, freed 
resources could be reinvested in potentially more cost-effective activities; such as efforts to 
improve screening uptake in higher risk non-attenders. 
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Conclusions 
A shift to biennial screening for individuals with Type 2 diabetes who have no retinopathy is 
likely to deliver significant savings for a very small increase in the risk of adverse visual 
acuity and quality of life outcomes. Given uncertainty over the longer term risk of 
progression in those who would be exposed continually to an extended interval, the safer 
strategies which target only those with no history of observed retinopathy may be preferred. 
Although our results suggest these safer strategies are also likely to be cost-effective in those 
with Type 1 diabetes, there is currently greater uncertainty surrounding the longer term cost 
and quality of life impact of any visual loss in this younger cohort. 
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FIGURE 1 Schematic of the model structure. 
FIGURE 2 Cost-effectiveness acceptability curves for the 2-year interval strategies, applied iteratively over a 
30-year time horizon. DR, diabetic retinopathy. 
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Table 1 Sample cohort characteristics based on data at last screen 
 
Whole cohort Type 1 diabetes Type 2 diabetes
Variable N Mean (SD) or n (%) N 
Mean (SD) or 
n (%) N 
Mean (SD) or 
n (%) 
Age, mean (SD) 7349 64.8 (15.1) 793 41.5 (16.3) 6523 67.7 (12.2) 
Duration, mean (SD) 7349 8.7 (8.0) 793 18.3 (12.9) 6523 7.5 (6.3)
ETDRS letters (left), mean (SD) 7223 75.4 (16.2) 793 80.6 (12.5) 6523 74.8 (16.4) 
ETDRS letters (right), mean (SD) 7222 75.3 (16.0) 793 80.3 (13.7) 6523 74.6 (16.2)
Type 2 diabetes; n (%)  7349 6523 (88.8) – – – – 
Male, n (%)  7349 4034 (54.9) 793 433 (54.6) 6523 3587 (55.0)
Current state, n (%)  7349 793  6523  
1 (R0/M0) 4843 (65.9) 335 (42.2)  4484 (68.7)
2 (R1) 1662 (22.6)  263 (33.2)  1391 (21.3) 
3 (M1, R2) 84 (1.1) 20 (2.5)  64 (1.0)
4 (R3, R4, M2) 478 (6.5)  160 (20.18)  317 (4.9) 
Missing 282 (3.84) 15 (1.89)  267 (4.1)
Previous state, n (%)  7349 793  6523  
1 (R0/M0) 3893 (53.0) 275 (34.7)  3603 (55.2)
2 (R1) 1417 (19.3)  256 (32.3)  1155 (17.7) 
3 (M1, R2) 88 (1.2) 22 (2.8)  66 (1.0)
4 (R3, R4, M2) 264 (3.59)  77 (9.7)  185 (2.8) 
NA 1287 (17.5) 140 (17.7)  1139 (17.5)
Missing 400 (5.44)  23 (2.9)  375 (5.8) 
ETDRS, Early Treatment of Diabetic Retinopathy Study; R0/M0, no retinopathy and no maculaopathy; R1, 
mild background retinopathy; R2 observable background retinopathy; M2, observable maculopathy; R3, 
referable background retinopathy; R4, proliferative retinopathy; M2, referable maculopathy; NA, not applicable. 
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Table 2 Costs and consequences of the alternative strategies at 3 years 
 
1. Current 
practice 
2. Two-year 
interval for 
all with no 
DR 
3. Two year 
interval for 
those with no 
DR and no DR 
previously 
observed 
4. Two year 
interval for 
those with no 
DR at two 
consecutive 
screens 
Total NHS costs (£) 213.88 192.79 195.18 199.67 
Incidence of referable 
disease (%) 
5.34 5.34 5.34 5.34 
Incidence of detected 
referable (%) 
3.00 2.96 2.98 2.99 
Incidence of MVL (per 
100 000) 
256 259 257 257 
Incidence of SVL or 
vitrectomy (per 
100 000) 
61 62 62 62 
Years free of MVL  2.73811 2.73807 2.73809 2.73809 
QALYs 2.25430 2.25430 2.25430 2.25430 
DR, diabetic retinopathy; no DR, no diabetic retinopathy; MVL (moderate visual loss ≥ 15 ETDRS letters); 
SVL (severe visual loss ≤ 25 ETDRS letters); bold type highlights the strategy most favoured on each outcome. 
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Table 3 Costs and consequences of applying the alternative strategies iteratively over time (30-year time 
horizon) 
  
1. 
Current 
practice 
2. Two-year 
interval for 
all with no 
DR 
3. Two-year 
interval for those 
with no DR and no 
DR previously 
observed 
4. Two-year 
interval for those 
with no DR at two 
consecutive 
screens 
Total NHS costs (£) 2016.59 1921.00 1930.80 1935.76 
Incidence of referable disease 
(%) 
34.79 34.79 34.79 34.79 
Incidence of detected referable 
(%) 
32.59 32.39 32.45 32.46 
Incidence of MVL (per 
100 000) 
13 012 13 066 13 048 13 048 
Incidence of SVL or 
vitrectomy (per 100 000) 
5 910 5 956 5 942 5 942 
Years free of MVL  10.736 10.732 10.733 10.733 
QALYs 9.1678 9.1673 9.1674 9.1675 
DR, diabetic retinopathy; no DR, no diabetic retinopathy; MVL (moderate visual loss ≥ 15 ETDRS letters); 
SVL (severe visual loss ≤ 25 letters). 
 
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 4 Estimated mean and incremental costs and QALYs for the alternative interval strategies applied 
iteratively over 30 years 
 
Mean cost 
(£) 
Incremental 
cost (£) 
Mean 
QALYs 
Incremental 
QALY 
ICER/QALY 
(£) 
Net 
monetary 
benefit 
(£) 
2. Two-year interval 
for those with no DR 
1 921.00  9.16731   £273 098 
3. Two-year interval 
for those with no DR 
and no DR previously 
recorded 
1 930.80 10 9.16744 0.000132 £73 960 £273 092 
4. Two-year interval 
for those with no DR 
at two consecutive 
screens 
1 935.76 5 9.16745 0.000010 £480 006 £273 088 
1. Current practice 2 016.59 81 9.16780 0.000348 £232 290 £273 017
Strategies compared incrementally to the next less effective, non-dominated alternative. DR, diabetic 
retinopathy; ICER, incremental cost-effectiveness ratio. 
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